# AMGN catalysts: AMGEN INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/amgn/catalysts

> AMGEN INC (AMGN) has 92 upcoming catalysts. The next is the ABP-234 topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | AMGEN INC |
| Ticker | AMGN (Nasdaq) |
| SEC CIK | 318154 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/amgn |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 27, 2015 | [Repatha (evolocumab) complete response letter (CRL)](https://sec-api.dev/pdufa/evolocumab) | AMGN |  | completed, complete response letter | "We have completed the review of BLA 125522/Original 2, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22125522Orig2s000OtherActionLtrs.pdf%22)) |
| September 23, 2016 | [Amjevita (adalimumab-atto) FDA approval](https://sec-api.dev/pdufa/adalimumab-atto) | AMGN |  | completed, approved | "BLA761024 ORIG-1 (Type 2 New Active Ingredient and Type 4 New Combination): submission_status AP, submission_status_date 20160923, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22)) |
| July 13, 2017 | [Evenity (romosozumab-aqqg) complete response letter (CRL)](https://sec-api.dev/pdufa/romosozumab-aqqg) | AMGN |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761062_2019_Orig1s000OtherActionLtrs.pdf%22)) |
| September 14, 2017 | [Mvasi (bevacizumab-awwb) FDA approval](https://sec-api.dev/pdufa/bevacizumab-awwb) | AMGN |  | completed, approved | "BLA761028 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20170914, review_priority STANDARD; sponsor_name AMGEN INC; product MVASI (BEVACIZUMAB-AWWB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761028%22)) |
| May 17, 2018 | [Aimovig (erenumab-aooe) FDA approval](https://sec-api.dev/pdufa/erenumab-aooe) | AMGN |  | completed, approved | "BLA761077 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180517, review_priority STANDARD; sponsor_name AMGEN INC; product AIMOVIG (ERENUMAB-AOOE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761077%22)) |
| May 25, 2018 | [Kanjinti (trastuzumab-anns) complete response letter (CRL)](https://sec-api.dev/pdufa/trastuzumab-anns) | AMGN |  | completed, complete response letter | "We have completed our review of this application, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22761073_2019_Orig1s000OtherActionLtrs.pdf%22)) |
| April 9, 2019 | [Evenity (romosozumab-aqqg) FDA approval](https://sec-api.dev/pdufa/romosozumab-aqqg) | AMGN |  | completed, approved | "BLA761062 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190409, review_priority STANDARD; sponsor_name AMGEN INC; product EVENITY (ROMOSOZUMAB-AQQG)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761062%22)) |
| April 22, 2019 | [Corlanor (ivabradine) FDA approval](https://sec-api.dev/pdufa/ivabradine) | AMGN |  | completed, approved | "NDA209964 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20190422, review_priority PRIORITY; sponsor_name AMGEN INC; product CORLANOR (IVABRADINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209964%22)) |
| June 13, 2019 | [Kanjinti (trastuzumab-anns) FDA approval](https://sec-api.dev/pdufa/trastuzumab-anns) | AMGN |  | completed, approved | "BLA761073 ORIG-1: submission_status AP, submission_status_date 20190613, review_priority STANDARD; sponsor_name AMGEN INC; product KANJINTI (TRASTUZUMAB-ANNS)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761073%22)) |
| December 6, 2019 | [Avsola (infliximab-axxq) FDA approval](https://sec-api.dev/pdufa/infliximab-axxq) | AMGN |  | completed, approved | "BLA761086 ORIG-1: submission_status AP, submission_status_date 20191206, review_priority STANDARD; sponsor_name AMGEN INC; product AVSOLA (INFLIXIMAB-AXXQ)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761086%22)) |
| January 21, 2020 | [Tepezza (teprotumumab-trbw) FDA approval](https://sec-api.dev/pdufa/teprotumumab-trbw) | AMGN |  | completed, approved | "BLA761143 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200121, review_priority PRIORITY; sponsor_name HORIZON THERAPEUTICS IRELAND; product TEPEZZA (TEPROTUMUMAB-TRBW)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761143%22)) |
| April 10, 2020 | [Otezla (apremilast) label expansion decision](https://sec-api.dev/pdufa/apremilast) | AMGN |  | completed, approved | "NDA205437 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20200410, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205437%22)) |
| June 9, 2020 | [Prolia® (denosumab) label expansion decision](https://sec-api.dev/pdufa/denosumab) | AMGN |  | completed, approved | "BLA125320 SUPPL-203 (Efficacy): submission_status AP, submission_status_date 20200609, review_priority STANDARD; sponsor_name AMGEN; product PROLIA (DENOSUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125320%22)) |
| December 17, 2020 | [Riabni (rituximab-arrx) FDA approval](https://sec-api.dev/pdufa/rituximab-arrx) | AMGN |  | completed, approved | "BLA761140 ORIG-1: submission_status AP, submission_status_date 20201217, review_priority STANDARD; sponsor_name AMGEN INC; product RIABNI (RITUXIMAB-ARRX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761140%22)) |
| January 28, 2021 | [Nplate (romiplostim) label expansion decision](https://sec-api.dev/pdufa/romiplostim) | AMGN |  | completed, approved | "BLA125268 SUPPL-167 (Efficacy): submission_status AP, submission_status_date 20210128, review_priority PRIORITY; sponsor_name AMGEN; product NPLATE (ROMIPLOSTIM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125268%22)) |
| February 26, 2021 | [Repatha (evolocumab) FDA approval](https://sec-api.dev/pdufa/evolocumab) | AMGN |  | completed, approved | "BLA125522 ORIG-2 (Efficacy): submission_status AP, submission_status_date 20210226, review_priority STANDARD; sponsor_name AMGEN INC; product REPATHA (EVOLOCUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125522%22)) |
| March 11, 2021 | [BLINCYTO® (blinatumomab) label expansion decision](https://sec-api.dev/pdufa/blinatumomab) | AMGN |  | completed, approved | "BLA125557 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20210311, review_priority PRIORITY; sponsor_name AMGEN; product BLINCYTO (BLINATUMOMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125557%22)) |
| May 28, 2021 | [LUMYKRAS™ (sotorasib) FDA approval](https://sec-api.dev/pdufa/sotorasib) | AMGN |  | completed, approved | "NDA214665 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210528, review_priority PRIORITY; sponsor_name AMGEN INC; product LUMAKRAS (SOTORASIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214665%22)) |
| September 24, 2021 | [Repatha (evolocumab) label expansion decision](https://sec-api.dev/pdufa/evolocumab) | AMGN |  | completed, approved | "BLA125522 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20210924, review_priority STANDARD; sponsor_name AMGEN INC; product REPATHA (EVOLOCUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125522%22)) |
| November 15, 2021 | [Mvasi (bevacizumab-awwb) label expansion decision](https://sec-api.dev/pdufa/bevacizumab-awwb) | AMGN |  | completed, approved | "BLA761028 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20211115, review_priority STANDARD; sponsor_name AMGEN INC; product MVASI (BEVACIZUMAB-AWWB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761028%22)) |
| December 20, 2021 | [Otezla (apremilast) label expansion decision](https://sec-api.dev/pdufa/apremilast) | AMGN |  | completed, approved | "NDA205437 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20211220, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205437%22)) |
| June 3, 2022 | [Riabni (rituximab-arrx) label expansion decision](https://sec-api.dev/pdufa/rituximab-arrx) | AMGN |  | completed, approved | "BLA761140 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20220603, review_priority STANDARD; sponsor_name AMGEN INC; product RIABNI (RITUXIMAB-ARRX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761140%22)) |
| July 28, 2022 | [Amjevita (adalimumab-atto) label expansion decision](https://sec-api.dev/pdufa/adalimumab-atto) | AMGN |  | completed, approved | "BLA761024 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20220728, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22)) |
| October 3, 2022 | [Aimovig (erenumab-aooe) label expansion decision](https://sec-api.dev/pdufa/erenumab-aooe) | AMGN |  | completed, approved | "BLA761077 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20221003, review_priority STANDARD; sponsor_name AMGEN INC; product AIMOVIG (ERENUMAB-AOOE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761077%22)) |
| Mar 2023 | [LUMYKRAS™ (sotorasib) complete response letter (CRL)](https://sec-api.dev/pdufa/sotorasib) | AMGN |  | completed, complete response letter | "Following our submission of the LUMAKRAS/LUMYKRAS CodeBreaK 200 Phase 3 confirmatory data in March 2023 to the FDA and EMA, we received a Complete Response Letter from the FDA and a new postmarketing requirement for an additional confirmatory study to support full approval." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/amgn-20260930.htm)) |
| March 22, 2023 | [Amjevita (adalimumab-atto) label expansion decision](https://sec-api.dev/pdufa/adalimumab-atto) | AMGN |  | completed, approved | "BLA761024 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20230322, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22)) |
| June 20, 2023 | [BLINCYTO® (blinatumomab) label expansion decision](https://sec-api.dev/pdufa/blinatumomab) | AMGN |  | completed, approved | "BLA125557 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20230620, review_priority UNKNOWN; sponsor_name AMGEN; product BLINCYTO (BLINATUMOMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125557%22)) |
| July 20, 2023 | [Otezla (apremilast) label expansion decision](https://sec-api.dev/pdufa/apremilast) | AMGN |  | completed, approved | "NDA205437 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20230720, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205437%22)) |
| August 14, 2023 | [Amjevita (adalimumab-atto) label expansion decision](https://sec-api.dev/pdufa/adalimumab-atto) | AMGN |  | completed, approved | "BLA761024 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20230814, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22)) |
| October 5, 2023 | [LUMYKRAS™ (sotorasib) FDA advisory committee meeting](https://sec-api.dev/pdufa/sotorasib) | AMGN |  | completed, negative | "The Committee will discuss supplemental new drug application (sNDA) 214665/S-005, for LUMAKRAS (sotorasib) tablets, submitted by Amgen Inc., for the proposed treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least one prior systemic therapy." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-5-2023-meeting-oncologic-drugs-advisory-committee-meeting-announcement-10052023)) |
| October 31, 2023 | [Wezlana (ustekinumab-auub) FDA approval](https://sec-api.dev/pdufa/ustekinumab-auub) | AMGN |  | completed, approved | "BLA761331 ORIG-1: submission_status AP, submission_status_date 20231031, review_priority STANDARD; sponsor_name AMGEN INC; product WEZLANA (USTEKINUMAB-AUUB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761331%22)) |
| March 5, 2024 | [Prolia® (denosumab) label expansion decision](https://sec-api.dev/pdufa/denosumab) | AMGN |  | completed, approved | "BLA125320 SUPPL-213 (Efficacy): submission_status AP, submission_status_date 20240305, review_priority STANDARD; sponsor_name AMGEN; product PROLIA (DENOSUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125320%22)) |
| April 25, 2024 | [Otezla (apremilast) label expansion decision](https://sec-api.dev/pdufa/apremilast) | AMGN |  | completed, approved | "NDA205437 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20240425, review_priority PRIORITY; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205437%22)) |
| May 16, 2024 | [Imdelltra (tarlatamab-dlle) FDA approval](https://sec-api.dev/pdufa/tarlatamab-dlle) | AMGN | To treat extensive stage small cell lung cancer | completed, approved | "Imdelltra \| tarlatamab-dlle \| 5/16/2024 \| To treat extensive stage small cell lung cancerDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| May 28, 2024 | [Bkemv (eculizumab-aeeb) FDA approval](https://sec-api.dev/pdufa/eculizumab-aeeb) | AMGN |  | completed, approved | "BLA761333 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20240528, review_priority STANDARD; sponsor_name AMGEN INC; product BKEMV (ECULIZUMAB-AEEB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761333%22)) |
| Jun 2024 | [BLINCYTO® (blinatumomab) FDA approval](https://sec-api.dev/pdufa/blinatumomab) | AMGN |  | completed, approved | "In June 2024, we announced BLINCYTO received approval from the FDA in frontline consolidation for patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/amgn-20241231.htm)) |
| Jun 2024 | [UPLIZNA® (inebilizumab) topline data readout](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Immunoglobulin G4-related disease | completed, positive | "In June 2024, we announced positive top-line results from our Phase 3 registrational trial evaluating UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/amgn-20241231.htm)) |
| June 14, 2024 | [BLINCYTO® (blinatumomab) label expansion decision](https://sec-api.dev/pdufa/blinatumomab) | AMGN |  | completed, approved | "BLA125557 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20240614, review_priority PRIORITY; sponsor_name AMGEN; product BLINCYTO (BLINATUMOMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125557%22)) |
| August 20, 2024 | [Amjevita (adalimumab-atto) label expansion decision](https://sec-api.dev/pdufa/adalimumab-atto) | AMGN |  | completed, approved | "BLA761024 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20240820, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22)) |
| August 23, 2024 | [Pavblu (aflibercept-ayyh) FDA approval](https://sec-api.dev/pdufa/aflibercept-ayyh) | AMGN |  | completed, approved | "BLA761298 ORIG-1: submission_status AP, submission_status_date 20240823, review_priority STANDARD; sponsor_name AMGEN INC; product PAVBLU (AFLIBERCEPT-AYYH)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761298%22)) |
| Nov 2024 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AMGN | severe chronic rhinosinusitis with nasal polyps | completed, positive | "In November 2024, we announced positive top-line results from the Phase 3 WAYPOINT trial, a double-blind, multi-center, randomized, placebo-controlled, parallel group trial designed to evaluate the efficacy and safety of TEZSPIRE in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/amgn-20241231.htm)) |
| December 26, 2024 | [Wezlana (ustekinumab-auub) label expansion decision](https://sec-api.dev/pdufa/ustekinumab-auub) | AMGN |  | completed, approved | "BLA761285 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20241226, review_priority STANDARD; sponsor_name AMGEN INC; product WEZLANA (USTEKINUMAB-AUUB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761285%22)) |
| Jan 2025 | [Vectibix® (panitumumab) FDA approval](https://sec-api.dev/pdufa/panitumumab) | AMGN |  | completed, approved | "•In January 2025, the FDA approved LUMAKRAS in combination with Vectibix as a targeted, biomarker-driven combination therapy for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/amgn-20241231earningsrelea.htm)) |
| January 16, 2025 | [Vectibix® (panitumumab) label expansion decision](https://sec-api.dev/pdufa/panitumumab) | AMGN |  | completed, approved | "BLA125147 SUPPL-213 (Efficacy): submission_status AP, submission_status_date 20250116, review_priority PRIORITY; sponsor_name AMGEN; product VECTIBIX (PANITUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125147%22)) |
| January 16, 2025 | [LUMYKRAS™ (sotorasib) label expansion decision](https://sec-api.dev/pdufa/sotorasib) | AMGN |  | completed, approved | "NDA214665 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20250116, review_priority PRIORITY; sponsor_name AMGEN INC; product LUMAKRAS (SOTORASIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214665%22)) |
| February 4, 2025 | [AMGEN INC FDA approval](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed, approved | "As of February 4, 2025, we have 25 phase 3 programs being studied in investigational indications, as five programs initiated phase 3 studies, three programs were approved by the FDA and one program was approved in Japan." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/amgn-20241231.htm)) |
| February 4, 2025 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/amgn-20241231earningsrelea.htm)) |
| Apr 2025 | [UPLIZNA® (inebilizumab) FDA approval](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Immunoglobulin G4-related disease | completed, approved | "In April 2025, we announced the FDA approved UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm)) |
| April 3, 2025 | [AMGEN INC PDUFA date](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | scheduled | "•The FDA accepted the regulatory submission for the Phase 3 MITIGATE study under priority review with a Prescription Drug User Fee Act (PDUFA) action date of April 3, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/amgn-20241231earningsrelea.htm)) |
| April 7, 2025 | [Amjevita (adalimumab-atto) label expansion decision](https://sec-api.dev/pdufa/adalimumab-atto) | AMGN |  | completed, approved | "BLA761024 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20250407, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22)) |
| May 1, 2025 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000018/amgn-20250331earningsrelea.htm)) |
| May 8, 2025 | [Daxdilimab primary completion](https://sec-api.dev/pdufa/daxdilimab) | AMGN | Discoid Lupus Erythematosus | withdrawn | "NCT05591222 (Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05591222)) |
| May 20, 2025 | [Amjevita (adalimumab-atto) label expansion decision](https://sec-api.dev/pdufa/adalimumab-atto) | AMGN |  | completed, approved | "BLA761024 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20250520, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22)) |
| May 22, 2025 | [Prolia® (denosumab) label expansion decision](https://sec-api.dev/pdufa/denosumab) | AMGN |  | completed, approved | "BLA125320 SUPPL-219 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name AMGEN; product PROLIA (DENOSUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125320%22)) |
| May 28, 2025 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Non-small Cell Lung Cancer | withdrawn | "NCT04933695 (A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04933695)) |
| June 20, 2025 | [Bemarituzumab primary completion](https://sec-api.dev/pdufa/bemarituzumab) | AMGN | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | completed | "NCT05052801 (Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-20 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05052801)) |
| 2H 2025 | [BLINCYTO® (blinatumomab) trial start](https://sec-api.dev/pdufa/blinatumomab) | AMGN |  | scheduled | "The Company is planning to initiate a potentially registration-enabling Phase 2 portion of this study in both adults and adolescents in H2 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250630earningsrelea.htm)) |
| 2H 2025 | [AMGEN INC topline data readout](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | scheduled | "Phase 3 data readout is anticipated in H2 2025/H1 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250630earningsrelea.htm)) |
| July 2, 2025 | [Daxdilimab primary completion](https://sec-api.dev/pdufa/daxdilimab) | AMGN | Idiopathic Inflammatory Myositis | completed | "NCT05669014 (A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-02 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-08-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669014)) |
| July 16, 2025 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Colorectal Cancer (CRC) | completed | "NCT05198934 (Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-16 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05198934)) |
| July 23, 2025 | [Otezla (apremilast) label expansion decision](https://sec-api.dev/pdufa/apremilast) | AMGN |  | completed, approved | "NDA205437 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20250723, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205437%22)) |
| July 25, 2025 | [Repatha (evolocumab) primary completion](https://sec-api.dev/pdufa/evolocumab) | AMGN | Coronary Heart Disease (CHD) | completed | "NCT03872401 (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-06-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03872401)) |
| July 31, 2025 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Atopic Dermatitis | completed | "NCT05633355 (A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-31 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05633355)) |
| August 5, 2025 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250630earningsrelea.htm)) |
| August 29, 2025 | [Otezla (apremilast) FDA approval](https://sec-api.dev/pdufa/apremilast) | AMGN |  | completed, approved | "NDA210745 ORIG-2 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250829, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210745%22)) |
| Q4 2025 | [AMGEN INC topline data readout](https://sec-api.dev/companies/amgn/catalysts) | AMGN | obesity or overweight, with or without T2D | scheduled | "•Part 2 of the Phase 2 chronic weight management study is ongoing in adults living with obesity or overweight, with or without T2D. Data readout is anticipated in Q4 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20250930earningsrelea.htm)) |
| Oct 2025 | [TEZSPIRE® (tezepelumab) FDA approval](https://sec-api.dev/pdufa/tezepelumab) | AMGN |  | completed, approved | "In October 2025, we announced that the FDA approved TEZSPIRE as an add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric patients aged 12 years and older." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm)) |
| October 6, 2025 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Type 2 Diabetes Mellitus (T2DM) | completed | "NCT06660173 (A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-06 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06660173)) |
| October 14, 2025 | [Bemarituzumab primary completion](https://sec-api.dev/pdufa/bemarituzumab) | AMGN | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | withdrawn | "NCT05111626 (Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05111626)) |
| October 19, 2025 | [AMGEN INC PDUFA date](https://sec-api.dev/companies/amgn/catalysts) | AMGN | chronic rhinosinusitis with nasal polyps | scheduled | "•FDA review of the WAYPOINT Phase 3 data in patients with chronic rhinosinusitis with nasal polyps is ongoing with a PDUFA date of October 19, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250630earningsrelea.htm)) |
| October 30, 2025 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Psoriasis | completed | "NCT04175613 (A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04175613)) |
| November 4, 2025 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20250930earningsrelea.htm)) |
| November 19, 2025 | [Erenumab dose 1 primary completion](https://sec-api.dev/pdufa/erenumab) | AMGN | Migraine | completed | "NCT03836040 (Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-19 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03836040)) |
| November 19, 2025 | [Imdelltra (tarlatamab-dlle) label expansion decision](https://sec-api.dev/pdufa/tarlatamab-dlle) | AMGN |  | completed, approved | "BLA761344 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority PRIORITY; sponsor_name AMGEN INC; product IMDELLTRA (TARLATAMAB-DLLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761344%22)) |
| November 20, 2025 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Plaque Psoriasis | completed | "NCT05565560 (A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-20 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05565560)) |
| Dec 2025 | [UPLIZNA® (inebilizumab) FDA approval](https://sec-api.dev/pdufa/inebilizumab) | AMGN | generalized myasthenia gravis | completed, approved | "In December 2025, we announced the FDA approved UPLIZNA for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm)) |
| December 14, 2025 | [AMGEN INC PDUFA date](https://sec-api.dev/companies/amgn/catalysts) | AMGN | generalized myasthenia gravis | scheduled | "•U.S. Food and Drug Administration (FDA) review of the MINT Phase 3 data in patients with generalized myasthenia gravis is ongoing, with a PDUFA date of December 14, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20250930earningsrelea.htm)) |
| December 18, 2025 | [IMDELLTRA® (tarlatamab) PDUFA date](https://sec-api.dev/pdufa/tarlatamab) | AMGN | relapsed ES-SCLC | scheduled | "•The U.S. regulatory submission of DeLLphi 304 a global Phase 3 confirmatory study evaluating IMDELLTRA vs. standard of care in subjects with relapsed ES-SCLC after platinum-based first-line chemotherapy was accepted with a PDUFA date of December 18, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20250930earningsrelea.htm)) |
| December 23, 2025 | [TEPEZZA® (teprotumumab) primary completion](https://sec-api.dev/pdufa/teprotumumab) | AMGN | Thyroid Eye Disease | completed | "NCT06248619 (A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-23 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06248619)) |
| 2026 | [UPLIZNA® (inebilizumab) trial start](https://sec-api.dev/pdufa/inebilizumab) | AMGN |  | scheduled | "•The Company expects to initiate Phase 3 studies of UPLIZNA in patients with autoimmune hepatitis and in patients with chronic inflammatory demyelinating polyneuropathy in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815426000003/amgn-20251231earningsrelea.htm)) |
| January 6, 2026 | [BLINCYTO® (blinatumomab) primary completion](https://sec-api.dev/pdufa/blinatumomab) | AMGN |  | completed | "NCT06054113 (Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-06 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06054113)) |
| February 3, 2026 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815426000003/amgn-20251231earningsrelea.htm)) |
| March 10, 2026 | [Nplate (romiplostim) primary completion](https://sec-api.dev/pdufa/romiplostim) | AMGN | Chemotherapy-induced Thrombocytopenia | completed | "NCT03937154 (Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-10 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03937154)) |
| Apr 2026 | [TEPEZZA® (teprotumumab) topline data readout](https://sec-api.dev/pdufa/teprotumumab) | AMGN | moderate-to-severe active thyroid eye disease | completed, positive | "In April 2026, we announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active thyroid eye disease (TED) that demonstrated that TEPEZZA OBI provides comparable efficacy to intravenous TEPEZZA (TEPEZZA IV)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/amgn-20260331.htm)) |
| April 17, 2026 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Prurigo Nodularis | withdrawn | "NCT06527404 (A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-04-17 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06527404)) |
| April 28, 2026 | [HZN-1116 primary completion](https://sec-api.dev/pdufa/hzn-1116) | AMGN | Sjogren's Syndrome | withdrawn | "NCT06312020 (A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-28 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06312020)) |
| April 30, 2026 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815426000054/amgn-20260331earningsrelea.htm)) |
| May 14, 2026 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Asthma | withdrawn | "NCT06376045 (A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-14 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06376045)) |
| June 25, 2026 | [Repatha (evolocumab) topline data readout](https://sec-api.dev/pdufa/evolocumab) | AMGN | Coronary Heart Disease (CHD) | completed | "NCT03872401 (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-06-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03872401?tab=results)) |
| July 1, 2026 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Atopic Dermatitis | withdrawn | "NCT05882877 (A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-07-01 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05882877)) |
| July 22, 2026 | [LUMYKRAS™ (sotorasib) topline data readout](https://sec-api.dev/pdufa/sotorasib) | AMGN | Colorectal Cancer (CRC) | completed | "NCT05198934 (Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-16 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05198934?tab=results)) |
| July 23, 2026 | [Dazodalibep primary completion](https://sec-api.dev/pdufa/dazodalibep) | AMGN | Sjogren's Syndrome | completed | "NCT06104124 (A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-23 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104124)) |
| July 24, 2026 | [Rocatinlimab topline data readout](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Atopic Dermatitis | completed | "NCT05633355 (A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-31 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05633355?tab=results)) |
| August 4, 2026 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815426000124/amgn-20260630earningsrelea.htm)) |
| August 12, 2026 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Plaque Psoriasis | completed | "NCT06088199 (A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06088199)) |
| Aug to Nov 2026 | [Otezla (apremilast) topline data readout](https://sec-api.dev/pdufa/apremilast) | AMGN | Plaque Psoriasis | scheduled | "NCT06088199 (A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06088199)) |
| August 25, 2026 | [Daxdilimab topline data readout](https://sec-api.dev/pdufa/daxdilimab) | AMGN | Idiopathic Inflammatory Myositis | completed | "NCT05669014 (A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-02 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-08-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669014?tab=results)) |
| Sep 2026 | [AMGEN INC topline data readout](https://sec-api.dev/companies/amgn/catalysts) | AMGN | Sjögren's disease and moderate-to-severe systemic disease activity | completed, positive | "In September 2026, we announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/amgn-20260930.htm)) |
| Oct 2026 to Jan 2027 | [Dazodalibep topline data readout](https://sec-api.dev/pdufa/dazodalibep) | AMGN | Sjögren's Syndrome (SS) | scheduled | "NCT06245408 (A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-22 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06245408)) |
| Oct 2026 to Jan 2027 | [Anvumetostat topline data readout](https://sec-api.dev/pdufa/anvumetostat) | AMGN | MTAP-deleted NSCLC | scheduled | "NCT06593522 (A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06593522)) |
| October 9, 2026 | [Repatha (evolocumab) label expansion decision](https://sec-api.dev/pdufa/evolocumab) | AMGN |  | completed, approved | "BLA125522 SUPPL-47 (Efficacy): submission_status AP, submission_status_date 20261009, review_priority STANDARD; sponsor_name AMGEN INC; product REPATHA (EVOLOCUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125522%22)) |
| October 22, 2026 | [Pavblu (aflibercept-ayyh) FDA approval](https://sec-api.dev/pdufa/aflibercept-ayyh) | AMGN |  | completed, approved | "BLA761298 ORIG-2: submission_status AP, submission_status_date 20261022, review_priority STANDARD; sponsor_name AMGEN INC; product PAVBLU (AFLIBERCEPT-AYYH)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761298%22)) |
| October 2026 | [Dazodalibep primary completion](https://sec-api.dev/pdufa/dazodalibep) | AMGN | Sjögren's Syndrome (SS) | delayed | "NCT06245408 (A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-22 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06245408)) |
| October 2026 | [Anvumetostat primary completion](https://sec-api.dev/pdufa/anvumetostat) | AMGN | MTAP-deleted NSCLC | delayed | "NCT06593522 (A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06593522)) |
| November 3, 2026 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815426000153/amgn-20260930earningsrelea.htm)) |
| Dec 2026 to Mar 2027 | [ABP-234 topline data readout](https://sec-api.dev/pdufa/abp-234) | AMGN | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06430866 (Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06430866)) |
| December 2026 | [ABP-234 primary completion](https://sec-api.dev/pdufa/abp-234) | AMGN | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06430866 (Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06430866)) |
| Jan to Apr 2027 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity | scheduled | "NCT06858839 (Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06858839)) |
| Jan to Apr 2027 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | scheduled | "NCT06858878 (Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06858878)) |
| January 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity | scheduled | "NCT06858839 (Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06858839)) |
| January 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | scheduled | "NCT06858878 (Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-21 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06858878)) |
| Apr to Jul 2027 | [UPLIZNA® (inebilizumab) topline data readout](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Neuromyelitis Optica Spectrum Disorder | scheduled | "NCT05549258 (Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-13 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05549258)) |
| Apr to Jul 2027 | [ABP-692 topline data readout](https://sec-api.dev/pdufa/abp-692) | AMGN | Relapsing-remitting Multiple Sclerosis (RRMS) | scheduled | "NCT06700343 (Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-19 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06700343)) |
| Apr to Jul 2027 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity Disease | scheduled | "NCT06987695 (Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-27 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06987695)) |
| April 2027 | [UPLIZNA® (inebilizumab) primary completion](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Neuromyelitis Optica Spectrum Disorder | scheduled | "NCT05549258 (Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-13 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05549258)) |
| April 2027 | [ABP-692 primary completion](https://sec-api.dev/pdufa/abp-692) | AMGN | Relapsing-remitting Multiple Sclerosis (RRMS) | scheduled | "NCT06700343 (Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-19 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06700343)) |
| April 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity Disease | scheduled | "NCT06987695 (Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-27 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06987695)) |
| May to Aug 2027 | [Romosozumab topline data readout](https://sec-api.dev/pdufa/romosozumab) | AMGN | Osteogenesis Imperfecta | scheduled | "NCT05972551 (Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05972551)) |
| May 2027 | [Romosozumab primary completion](https://sec-api.dev/pdufa/romosozumab) | AMGN | Osteogenesis Imperfecta | scheduled | "NCT05972551 (Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05972551)) |
| Jun to Sep 2027 | [Etelcalcetide topline data readout](https://sec-api.dev/pdufa/etelcalcetide) | AMGN | Secondary Hyperparathyroidism | scheduled | "NCT03969329 (A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03969329)) |
| Jun to Sep 2027 | [LUMYKRAS™ (sotorasib) topline data readout](https://sec-api.dev/pdufa/sotorasib) | AMGN | Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT05920356 (A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05920356)) |
| Jun to Sep 2027 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Overweight | scheduled | "NCT07871409 (Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-16 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871409)) |
| June 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Overweight | scheduled | "NCT07871409 (Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-16 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871409)) |
| June 2027 | [Etelcalcetide primary completion](https://sec-api.dev/pdufa/etelcalcetide) | AMGN | Secondary Hyperparathyroidism | scheduled | "NCT03969329 (A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03969329)) |
| June 2027 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT05920356 (A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05920356)) |
| Jul to Oct 2027 | [Avacopan topline data readout](https://sec-api.dev/pdufa/avacopan) | AMGN | Vasculitis | scheduled | "NCT06321601 (Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-18 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06321601)) |
| Jul to Oct 2027 | [Abp 938 8 mg topline data readout](https://sec-api.dev/pdufa/abp-938) | AMGN | Neovascular Age-related Macular Degeneration; nAMD | scheduled | "NCT07614776 (A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614776)) |
| July 2027 | [Avacopan primary completion](https://sec-api.dev/pdufa/avacopan) | AMGN | Vasculitis | scheduled | "NCT06321601 (Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-18 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06321601)) |
| July 2027 | [Abp 938 8 mg primary completion](https://sec-api.dev/pdufa/abp-938) | AMGN | Neovascular Age-related Macular Degeneration; nAMD | scheduled | "NCT07614776 (A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614776)) |
| Aug to Nov 2027 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Obstructive Sleep Apnea | scheduled | "NCT07225686 (Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-20 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225686)) |
| Aug to Nov 2027 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obstructive Sleep Apnea | scheduled | "NCT07226765 (Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226765)) |
| Aug to Nov 2027 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Overweight or Obesity and Elevated Liver Fat | scheduled | "NCT07441252 (A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441252)) |
| August 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Obstructive Sleep Apnea | scheduled | "NCT07225686 (Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-20 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225686)) |
| August 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Overweight or Obesity and Elevated Liver Fat | scheduled | "NCT07441252 (A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441252)) |
| August 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obstructive Sleep Apnea | scheduled | "NCT07226765 (Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226765)) |
| Sep to Dec 2027 | [IMDELLTRA® (tarlatamab) topline data readout](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Small Cell Lung Cancer | scheduled | "NCT07778316 (Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07778316)) |
| September 2027 | [IMDELLTRA® (tarlatamab) primary completion](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Small Cell Lung Cancer | scheduled | "NCT07778316 (Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07778316)) |
| Dec 2027 to Mar 2028 | [IMDELLTRA® (tarlatamab) topline data readout](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Relapsed/Refractory Small Cell Lung Cancer | scheduled | "NCT05060016 (A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05060016)) |
| Dec 2027 to Mar 2028 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Overweight; Diabetes Mellitus, Type 2 | scheduled | "NCT07684144 (Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-26 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684144)) |
| Dec 2027 to Mar 2028 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Overweight | scheduled | "NCT07684235 (Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-26 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684235)) |
| December 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Overweight; Diabetes Mellitus, Type 2 | scheduled | "NCT07684144 (Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-26 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684144)) |
| December 2027 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity; Overweight | scheduled | "NCT07684235 (Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-26 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07684235)) |
| December 2027 | [IMDELLTRA® (tarlatamab) primary completion](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Relapsed/Refractory Small Cell Lung Cancer | scheduled | "NCT05060016 (A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05060016)) |
| Jan to Apr 2028 | [ABP-206 topline data readout](https://sec-api.dev/pdufa/abp-206) | AMGN | Melanoma | scheduled | "NCT06054555 (A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06054555)) |
| Jan to Apr 2028 | [ABP-234 topline data readout](https://sec-api.dev/pdufa/abp-234) | AMGN | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | scheduled | "NCT06311721 (A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06311721)) |
| Jan to Apr 2028 | [AMG-732 topline data readout](https://sec-api.dev/pdufa/amg-732) | AMGN | Thyroid Eye Disease | scheduled | "NCT07438405 (An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-29 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07438405)) |
| Jan to Apr 2028 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity or Overweight | scheduled | "NCT07575399 (Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-03 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07575399)) |
| January 2028 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity or Overweight | scheduled | "NCT07575399 (Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-03 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07575399)) |
| January 2028 | [ABP-234 primary completion](https://sec-api.dev/pdufa/abp-234) | AMGN | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | scheduled | "NCT06311721 (A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06311721)) |
| January 2028 | [ABP-206 primary completion](https://sec-api.dev/pdufa/abp-206) | AMGN | Melanoma | scheduled | "NCT06054555 (A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06054555)) |
| January 2028 | [AMG-732 primary completion](https://sec-api.dev/pdufa/amg-732) | AMGN | Thyroid Eye Disease | scheduled | "NCT07438405 (An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-29 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07438405)) |
| Mar to Jun 2028 | [Otezla (apremilast) topline data readout](https://sec-api.dev/pdufa/apremilast) | AMGN | Active Juvenile Psoriatic Arthritis | scheduled | "NCT04804553 (Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04804553)) |
| Mar to Jun 2028 | [Olpasiran topline data readout](https://sec-api.dev/pdufa/olpasiran) | AMGN | Atherosclerotic Cardiovascular Disease | scheduled | "NCT05581303 (Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05581303)) |
| March 2028 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Active Juvenile Psoriatic Arthritis | scheduled | "NCT04804553 (Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04804553)) |
| March 2028 | [Olpasiran primary completion](https://sec-api.dev/pdufa/olpasiran) | AMGN | Atherosclerotic Cardiovascular Disease | scheduled | "NCT05581303 (Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05581303)) |
| Apr to Jul 2028 | [AMGEN INC topline data readout](https://sec-api.dev/companies/amgn/catalysts) | AMGN | Osteogenesis Imperfecta | scheduled | "NCT07366086 (Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-19 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07366086)) |
| April 2028 | [AMGEN INC primary completion](https://sec-api.dev/companies/amgn/catalysts) | AMGN | Osteogenesis Imperfecta | scheduled | "NCT07366086 (Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-19 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07366086)) |
| Jun to Sep 2028 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Atherosclerotic Cardiovascular Disease; Overweight; Obesity | scheduled | "NCT07037433 (Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07037433)) |
| Jun to Sep 2028 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN |  | scheduled | "NCT07037459 (Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07037459)) |
| Jun to Sep 2028 | [Olpasiran topline data readout](https://sec-api.dev/pdufa/olpasiran) | AMGN | Cardiovascular Disease | scheduled | "NCT07293260 (Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-15 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07293260)) |
| Jun to Sep 2028 | [Pegloticase topline data readout](https://sec-api.dev/pdufa/pegloticase) | AMGN | Uncontrolled Gout | scheduled | "NCT07388498 (A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-18 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07388498)) |
| June 2028 | [Olpasiran primary completion](https://sec-api.dev/pdufa/olpasiran) | AMGN | Cardiovascular Disease | scheduled | "NCT07293260 (Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-15 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07293260)) |
| June 2028 | [Pegloticase primary completion](https://sec-api.dev/pdufa/pegloticase) | AMGN | Uncontrolled Gout | scheduled | "NCT07388498 (A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-18 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07388498)) |
| June 2028 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Atherosclerotic Cardiovascular Disease; Overweight; Obesity | scheduled | "NCT07037433 (Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07037433)) |
| June 2028 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN |  | scheduled | "NCT07037459 (Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07037459)) |
| July 2028 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Advanced Solid Tumors | scheduled | "NCT07172919 (A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07172919)) |
| Jul to Oct 2028 | [LUMYKRAS™ (sotorasib) topline data readout](https://sec-api.dev/pdufa/sotorasib) | AMGN | Advanced Solid Tumors | scheduled | "NCT07172919 (A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07172919)) |
| Aug to Nov 2028 | [BLINCYTO® (blinatumomab) topline data readout](https://sec-api.dev/pdufa/blinatumomab) | AMGN | Systemic Lupus Erythematosus; Active Refractory Rheumatoid Arthritis | scheduled | "NCT06570798 (A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-06 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06570798)) |
| August 2028 | [BLINCYTO® (blinatumomab) primary completion](https://sec-api.dev/pdufa/blinatumomab) | AMGN | Systemic Lupus Erythematosus; Active Refractory Rheumatoid Arthritis | scheduled | "NCT06570798 (A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-06 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06570798)) |
| Sep to Dec 2028 | [LUMYKRAS™ (sotorasib) topline data readout](https://sec-api.dev/pdufa/sotorasib) | AMGN | Metastatic Colorectal Cancer | scheduled | "NCT06252649 (Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06252649)) |
| Sep to Dec 2028 | [Maridebart cafraglutide topline data readout](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Diabetes Mellitus, Type 2 | scheduled | "NCT07866066 (Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-06 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07866066)) |
| September 2028 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Diabetes Mellitus, Type 2 | scheduled | "NCT07866066 (Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-06 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07866066)) |
| September 2028 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Metastatic Colorectal Cancer | scheduled | "NCT06252649 (Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06252649)) |
| Jan to Apr 2029 | [Etelcalcetide topline data readout](https://sec-api.dev/pdufa/etelcalcetide) | AMGN | Secondary Hyperparathyroidism; Chronic Kidney Disease | scheduled | "NCT03633708 (A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03633708)) |
| Jan to Apr 2029 | [Xaluritamig topline data readout](https://sec-api.dev/pdufa/xaluritamig) | AMGN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06691984 (Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06691984)) |
| Jan to Apr 2029 | [IMDELLTRA® (tarlatamab) topline data readout](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer | scheduled | "NCT07005128 (A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-04 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07005128)) |
| January 2029 | [Xaluritamig primary completion](https://sec-api.dev/pdufa/xaluritamig) | AMGN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06691984 (Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-02 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06691984)) |
| January 2029 | [IMDELLTRA® (tarlatamab) primary completion](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer | scheduled | "NCT07005128 (A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-01-04 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07005128)) |
| January 2029 | [Etelcalcetide primary completion](https://sec-api.dev/pdufa/etelcalcetide) | AMGN | Secondary Hyperparathyroidism; Chronic Kidney Disease | scheduled | "NCT03633708 (A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03633708)) |
| Aug to Nov 2029 | [IMDELLTRA® (tarlatamab) topline data readout](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Small Cell Lung Cancer (SCLC) | scheduled | "NCT06745323 (A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-08-10 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06745323)) |
| August 2029 | [IMDELLTRA® (tarlatamab) primary completion](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Small Cell Lung Cancer (SCLC) | scheduled | "NCT06745323 (A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-08-10 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06745323)) |
| Sep to Dec 2029 | [BLINCYTO® (blinatumomab) topline data readout](https://sec-api.dev/pdufa/blinatumomab) | AMGN |  | scheduled | "NCT04994717 (Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04994717)) |
| Sep to Dec 2029 | [Nplate (romiplostim) topline data readout](https://sec-api.dev/pdufa/romiplostim) | AMGN | Primary Immune Thrombocytopenia | scheduled | "NCT07700238 (A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07700238)) |
| September 2029 | [BLINCYTO® (blinatumomab) primary completion](https://sec-api.dev/pdufa/blinatumomab) | AMGN |  | scheduled | "NCT04994717 (Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04994717)) |
| September 2029 | [Nplate (romiplostim) primary completion](https://sec-api.dev/pdufa/romiplostim) | AMGN | Primary Immune Thrombocytopenia | scheduled | "NCT07700238 (A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07700238)) |
| Dec 2029 to Mar 2030 | [Dazodalibep topline data readout](https://sec-api.dev/pdufa/dazodalibep) | AMGN | Sjögren's Syndrome | scheduled | "NCT06747949 (A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-11 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06747949)) |
| December 2029 | [Dazodalibep primary completion](https://sec-api.dev/pdufa/dazodalibep) | AMGN | Sjögren's Syndrome | scheduled | "NCT06747949 (A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-11 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06747949)) |
| Jan to Apr 2030 | [Xaluritamig topline data readout](https://sec-api.dev/pdufa/xaluritamig) | AMGN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT07213674 (A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-07 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213674)) |
| January 2030 | [Xaluritamig primary completion](https://sec-api.dev/pdufa/xaluritamig) | AMGN | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT07213674 (A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-07 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213674)) |
| Feb to May 2030 | [Otezla (apremilast) topline data readout](https://sec-api.dev/pdufa/apremilast) | AMGN | Behçet Disease | scheduled | "NCT04528082 (Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-07 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04528082)) |
| February 2030 | [Otezla (apremilast) primary completion](https://sec-api.dev/pdufa/apremilast) | AMGN | Behçet Disease | scheduled | "NCT04528082 (Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-02-07 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04528082)) |
| Mar to Jun 2030 | [UPLIZNA® (inebilizumab) topline data readout](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Generalized Myasthenia Gravis | scheduled | "NCT06987539 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-13 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06987539)) |
| March 2030 | [UPLIZNA® (inebilizumab) primary completion](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Generalized Myasthenia Gravis | scheduled | "NCT06987539 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-13 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06987539)) |
| Apr to Jul 2030 | [IMDELLTRA® (tarlatamab) topline data readout](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer | scheduled | "NCT06117774 (Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-04-20 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06117774)) |
| Apr to Jul 2030 | [IMDELLTRA® (tarlatamab) topline data readout](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer | scheduled | "NCT06211036 (Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-04-02 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06211036)) |
| April 2030 | [IMDELLTRA® (tarlatamab) primary completion](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer | scheduled | "NCT06211036 (Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-04-02 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06211036)) |
| April 2030 | [IMDELLTRA® (tarlatamab) primary completion](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer | scheduled | "NCT06117774 (Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-04-20 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06117774)) |

## Drugs

- [ABP-206](https://sec-api.dev/pdufa/abp-206): Melanoma
- [ABP-234](https://sec-api.dev/pdufa/abp-234): Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC), Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
- [ABP-692](https://sec-api.dev/pdufa/abp-692): Relapsing-remitting Multiple Sclerosis (RRMS)
- [Abp 938 8 mg](https://sec-api.dev/pdufa/abp-938): Neovascular Age-related Macular Degeneration
- [Amjevita (adalimumab-atto)](https://sec-api.dev/pdufa/adalimumab-atto): 
- [Pavblu (aflibercept-ayyh)](https://sec-api.dev/pdufa/aflibercept-ayyh): 
- [AMG-732](https://sec-api.dev/pdufa/amg-732): Thyroid Eye Disease
- [Anvumetostat](https://sec-api.dev/pdufa/anvumetostat): MTAP-deleted NSCLC
- [Otezla (apremilast)](https://sec-api.dev/pdufa/apremilast): Plaque Psoriasis, Active Juvenile Psoriatic Arthritis, Psoriasis, Behçet Disease
- [Avacopan](https://sec-api.dev/pdufa/avacopan): Vasculitis
- [Bemarituzumab](https://sec-api.dev/pdufa/bemarituzumab): Gastric Cancer
- [Mvasi (bevacizumab-awwb)](https://sec-api.dev/pdufa/bevacizumab-awwb): 
- [BLINCYTO® (blinatumomab)](https://sec-api.dev/pdufa/blinatumomab): B Precursor Acute Lymphoblastic Leukemia, Systemic Lupus Erythematosus
- [Daxdilimab](https://sec-api.dev/pdufa/daxdilimab): Discoid Lupus Erythematosus, Idiopathic Inflammatory Myositis
- [Dazodalibep](https://sec-api.dev/pdufa/dazodalibep): Sjögren's Syndrome (SS), Sjögren's Syndrome, Sjogren's Syndrome
- [Prolia® (denosumab)](https://sec-api.dev/pdufa/denosumab): osteoporosis in women
- [Bkemv (eculizumab-aeeb)](https://sec-api.dev/pdufa/eculizumab-aeeb): 
- [Erenumab dose 1](https://sec-api.dev/pdufa/erenumab): Migraine
- [Aimovig (erenumab-aooe)](https://sec-api.dev/pdufa/erenumab-aooe): 
- [Etelcalcetide](https://sec-api.dev/pdufa/etelcalcetide): Secondary Hyperparathyroidism
- [Repatha (evolocumab)](https://sec-api.dev/pdufa/evolocumab): Coronary Heart Disease (CHD)
- [HZN-1116](https://sec-api.dev/pdufa/hzn-1116): Sjogren's Syndrome
- [UPLIZNA® (inebilizumab)](https://sec-api.dev/pdufa/inebilizumab): immunoglobulin g4-related disease, generalized myasthenia gravis, Neuromyelitis Optica Spectrum Disorder
- [Avsola (infliximab-axxq)](https://sec-api.dev/pdufa/infliximab-axxq): 
- [Corlanor (ivabradine)](https://sec-api.dev/pdufa/ivabradine): 
- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide): Overweight or Obesity and Elevated Liver Fat, Obstructive Sleep Apnea, Obesity, Diabetes Mellitus, Type 2, Atherosclerotic Cardiovascular Disease, Obesity or Overweight, Obesity Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM), Heart Failure With Preserved Ejection Fraction
- [Olpasiran](https://sec-api.dev/pdufa/olpasiran): Atherosclerotic Cardiovascular Disease, Cardiovascular Disease
- [Vectibix® (panitumumab)](https://sec-api.dev/pdufa/panitumumab): 
- [Pegloticase](https://sec-api.dev/pdufa/pegloticase): Uncontrolled Gout
- [Riabni (rituximab-arrx)](https://sec-api.dev/pdufa/rituximab-arrx): 
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab): Atopic Dermatitis, Prurigo Nodularis, Asthma
- [Nplate (romiplostim)](https://sec-api.dev/pdufa/romiplostim): Chemotherapy-induced Thrombocytopenia, Primary Immune Thrombocytopenia
- [Romosozumab](https://sec-api.dev/pdufa/romosozumab): Osteogenesis Imperfecta
- [Evenity (romosozumab-aqqg)](https://sec-api.dev/pdufa/romosozumab-aqqg): 
- [LUMYKRAS™ (sotorasib)](https://sec-api.dev/pdufa/sotorasib): Advanced Solid Tumors, Non-small Cell Lung Cancer, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), Metastatic Colorectal Cancer
- [IMDELLTRA® (tarlatamab)](https://sec-api.dev/pdufa/tarlatamab): relapsed es-sclc, Extensive-Stage Small-Cell Lung Cancer, Relapsed/Refractory Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Small Cell Lung Cancer, Small-cell Lung Cancer
- [Imdelltra (tarlatamab-dlle)](https://sec-api.dev/pdufa/tarlatamab-dlle): To treat extensive stage small cell lung cancer
- [TEPEZZA® (teprotumumab)](https://sec-api.dev/pdufa/teprotumumab): moderate-to-severe active thyroid eye disease, Thyroid Eye Disease
- [Tepezza (teprotumumab-trbw)](https://sec-api.dev/pdufa/teprotumumab-trbw): 
- [Kanjinti (trastuzumab-anns)](https://sec-api.dev/pdufa/trastuzumab-anns): 
- [Wezlana (ustekinumab-auub)](https://sec-api.dev/pdufa/ustekinumab-auub): 
- [Xaluritamig](https://sec-api.dev/pdufa/xaluritamig): Metastatic Castration-resistant Prostate Cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/amgn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AMGN catalysts: AMGEN INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/amgn/catalysts

```bibtex
@misc{secapidev_companies_amgn_catalysts_20261116,
  title        = {AMGN catalysts: AMGEN INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/amgn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_amgn_catalysts_20261116","title":"AMGN catalysts: AMGEN INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/amgn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
